Avacta Group plc (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss an agreement with AffyXell in S Korea. Alastair talks us through the details, explains the main focus for AffyXell and when investors should expect to hear on progress.
Avacta Group is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care Doxorubicin, into the clinic in the middle of 2020.
Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a deal with LG Chem worth up to $310m, and a partnership with ADC Therapeutics. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.